OmniRayn
← All repurposing reports
S3 (505(b)(2)+Orphan) · Orphan-eligible

progeria

Known, approved drugs ranked as repurposing candidates for progeria — each scored for reversal of the disease expression signature, cytotoxicity-filtered, and prioritized by clinical maturity. Computational, pending wet-lab.

Preview. Candidate identities are shown below. The full ranking, quantified reversal scores, per-candidate mechanistic rationale, ClinicalTrials.gov whitespace detail, and structure-function intelligence are included with the dossier.

Top candidates preview

  1. 1ruxolitinibApproved
  2. 2pravastatinApproved
  3. 3atorvastatinApproved
  4. 4fluspirileneApproved
  5. 5flutamideApproved
  6. 6salmeterolApproved
  7. 7dactinomycinApproved
  8. 8sulfinpyrazoneApproved

Full dossier — 146 cytotox-screened candidates

Quantified reversal ranking · mechanistic rationale · CT.gov whitespace · S3 (505(b)(2)+Orphan) regulatory framing · structure-function intelligence.

Acquire dossier — $3,950